The Infectious Diarrhea drugs in development market research report provides comprehensive information on the therapeutics under development for Infectious Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Infectious Diarrhea. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Infectious Diarrhea and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Infectious Diarrhea by 12 companies/universities/institutes. The top development phase for Infectious Diarrhea is preclinical with eight drugs in that stage. The Infectious Diarrhea pipeline has ten drugs in development by companies and three by universities/ institutes. Some of the companies in the Infectious Diarrhea pipeline products market are: Theriva Biologics, Napo Pharmaceuticals and Hilleman Laboratories.
The key targets in the Infectious Diarrhea pipeline products market include Cystic Fibrosis Transmembrane Conductance Regulator.
The key mechanisms of action in the Infectious Diarrhea pipeline product include Cystic Fibrosis Transmembrane Conductance Regulator Blocker with two drugs in Phase II. The Infectious Diarrhea pipeline products include two routes of administration with the top ROA being Oral and six key molecule types in the Infectious Diarrhea pipeline products market including Small Molecule, and Recombinant Enzyme.
Infectious Diarrhea overview
Infectious Diarrhea is a common gastrointestinal infection and the most common type of diarrhea. Diarrhea is defined as frequent bowel movements that are loose, watery, and associated with nausea, vomiting, and fatigue. Bacterial, viral, and protozoans are the common pathogens leading to infectious diarrhea. E. coli-associated infections are the most common bacteria while Entamoeba histolytica is a common parasite causing infectious diarrhea. The mode of infection can be through contaminated food, water, medications, and diseases like IBD. As there a several losses of body fluids or secretion oral rehydrating therapy is the primary treatment option to treat dehydration. Stool examination to analyze the pathogens, complete blood tests, and serum electrolytes are diagnostic methods. Abdominal pain, frequent bowel movements, nausea, and vomiting are common symptoms. Antibiotics, anti-diarrheal, and anti-emetics are common medications used.
For a complete picture of Infectious Diarrhea’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
